BioNotebook: Insys, TetraLogic, Corcept, Mallinckrodt, Celsus
This article was originally published in Scrip
Executive Summary
Insys subpoenaed regarding Subsys; TetraLogic prices IPO; Corcept adds oncology program; Mallinckrodt's MNK-155 study complete, NDA filing planned; and Celsus seeks US investors.